Simvastatin . sodium salt
| Code | Size | Price |
|---|
| AG-CN2-0539-M005 | 5 mg | £70.00 |
Quantity:
| AG-CN2-0539-M025 | 25 mg | £190.00 |
Quantity:
| AG-CN2-0539-M100 | 100 mg | £390.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short Term: +4°C, Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
MK-733; Synvinolin; BRN 4768037
Appearance:
White to off-white powder.
CAS:
101314-97-0
EClass:
32160000
Form (Short):
liquid
Handling Advice:
After reconstitution, prepare aliquots and store at -20°C.Aqueous solutions should not be stored for longer than one day.
InChi:
InChI=1S/C25H40O6.Na/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29;/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29);/q;+1/p-1/t15-,16-,18+,19+,20-,21-,23-;/m0./s1
InChiKey:
RLWRROYWKHUVKF-OKDJMAGBSA-M
Long Description:
Chemical. CAS: 101314-97-0. Formula: C25H39O6 . Na. MW: 458.6. Synthetic analog of Lovastatin (Prod. No. AG-CN2-0051 http://www.adipogen.com/ag-cn2-0051/lovastatin.html ). Water-soluble carboxylate form of Simvastatin (Prod.No. AG-CN2-0052 https://adipogen.com/ag-cn2-0052-simvastatin.html ). Potent competitive HMG-CoA reductase inhibitor [1]. Anti-hypercholesterolemic agent [1]. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids [1, 2]. Inhibits the isoprenylation of Ras and Rho family GTPases [2]. Smooth muscle cell proliferation inhibitor [3]. Anti-adhesive, immunomodulatory and anti-inflammatory compound [4, 7, 10]. Proteasome modulator [5]. Stimulates bone formation [6]. Apoptosis inducer [8]. Anticancer compound [8, 9]. Increases cellular resistance to anticancer agents such as doxorubicin and etoposides (Prod. No. AG-CR1-3572 http://www.adipogen.com/ag-cr1-3572/etoposide.html ) [9]. Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection [11, 12]. Anti-hypertensive agent [13]. Suppresses TNF-induced NF-kappaB activation [14].
MDL:
MFCD00072007
Molecular Formula:
C25H39O6 . Na
Molecular Weight:
435.6 . 23.0
Package Type:
Vial
Product Description:
Synthetic analog of Lovastatin (Prod. No. AG-CN2-0051 http://www.adipogen.com/ag-cn2-0051/lovastatin.html ). Water-soluble carboxylate form of Simvastatin (Prod.No. AG-CN2-0052 https://adipogen.com/ag-cn2-0052-simvastatin.html ). Potent competitive HMG-CoA reductase inhibitor [1]. Anti-hypercholesterolemic agent [1]. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids [1, 2]. Inhibits the isoprenylation of Ras and Rho family GTPases [2]. Smooth muscle cell proliferation inhibitor [3]. Anti-adhesive, immunomodulatory and anti-inflammatory compound [4, 7, 10]. Proteasome modulator [5]. Stimulates bone formation [6]. Apoptosis inducer [8]. Anticancer compound [8, 9]. Increases cellular resistance to anticancer agents such as doxorubicin and etoposides (Prod. No. AG-CR1-3572 http://www.adipogen.com/ag-cr1-3572/etoposide.html ) [9]. Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection [11, 12]. Anti-hypertensive agent [13]. Suppresses TNF-induced NF-kappaB activation [14].
Purity:
>98% (HPLC)
SMILES:
C[C@@H]1C[C@H](OC(C(CC)(C)C)=O)[C@@]2([H])C(C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C1.[Na+]
Solubility Chemicals:
Soluble in water (30mg/ml). Soluble in DMSO, ethanol or DMF (all 10mg/ml).
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia: M.J. Mol, et al.; Lancet 2, 936 (1986) | All ras proteins are polyisoprenylated but only some are palmitoylated: J.F. Hancock, et al.; Cell 57, 1167 (1989) | Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types: P. Negre-Aminou, et al.; Biochim. Biophys. Acta 1345, 259 (1997) | Statins as a newly recognized type of immunomodulator: B. Kwak, et al.; Nat. Med. 6, 1399 (2000) | Lovastatin and simvastatin are modulators of the proteasome: C. Wojcik, et al.; Int. J. Biochem. Cell Biol. 32, 957 (2000) | Statins and bone formation: I.R. Garrett, et al.; Curr. Pharm. Des. 7, 715 (2001) | HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection: L.J. Raggatt & N.C. Partridge; Drugs 62, 2185 (2002) (Review) | HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis: W.W. Wong, et al.; Leukemia 16, 508 (2002) | The statins as anticancer agents: K.K. Chan, et al.; Clin. Cancer Res. 9,10 (2003) | Anti-inflammatory and immunomodulatory effects of statins: L.M. Blanco-Colio, et al.; Kidney Int. 63, 12 (2003) | Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1: J.F. Giguere & M.J. Tremblay; J. Virol. 78, 12062 (2004) | HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma: J.I. Cohen; Br. J. Canc. 92, 1593 (2005) | Beyond lipid lowering: the anti-hypertensive role of statins: V. Chopra, et al.; Cardiovasc. Drugs Ther. 21, 161 (2007) | Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway: K.S. Ahn, et al.; Biochem. Pharmacol. 75, 907 (2008)